Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis
Status:
Recruiting
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
This clinical trial serves to look at the effectiveness of SWRB for the treatment of mild to
moderate Atopic Dermatitis in patients below the age of 18. Atopic Dermatitis (AD) is a
common condition seen in dermatology, paediatric and primary care clinics in Malaysia. AD
poses a significant biopsychosocial burden among sufferers and their families. Current
management patterns of AD sufferers in South-east Asia mainly involve use of topical
moisturizers and topical corticosteroids.
Rice bran and products derived from it have been studied regarding their anti-oxidant,
nutritional, cholesterol lowering and health promoting properties. However, there are very
few studies that have focused on the benefits of SWRB when used topically.
SWRB is cost-effective and easily available, while being an under-utilised product. The
investigators wanted to study its effectiveness in controlling the signs and symptoms of
Atopic Dermatitis when used as a cleanser and topical paste (emollient) as very little is
known on this subject.
The investigators wish to study participants below 18 years of age with mild and moderate
Atopic Dermatitis.
The participants will be followed up for four to six (4 - 6) weeks and the clinical features
tabulated. This study does not involve any enteral or parenteral administration of SWRB.
Neither does it involve any invasive procedures.